Which second-generation antipsychotic has been shown to decrease the QT interval?

Aripiprazole (Abilify) is notable among second-generation antipsychotics for its ability to decrease the QT interval. This characteristic is significant because prolonged QT interval can lead to serious cardiac arrhythmias. Unlike some other antipsychotics, which may pose a risk for QT interval prolongation, aripiprazole demonstrates a more favorable cardiac safety profile in this aspect.

Additionally, aripiprazole's unique pharmacological profile as a partial dopamine agonist contributes to its lower propensity to affect cardiac conduction compared to other antipsychotics, making it a suitable choice in terms of minimization of cardiovascular risk. This is particularly important for patients who may be sensitive to QT prolongation due to other medical conditions, concurrent medications, or personal risk factors.

In contrast, the other medications listed have varying effects on the QT interval, with some associated with risks of prolongation. Understanding these differences is crucial for optimizing treatment while considering cardiac safety.